Supplemental Material, Risk-Benefit_Manuscript_revised_supporting_material_20171025a_w_tables2 - Analysis of the Risks and Benefits of New Chemical Entities Approved by the US Food and Drug Administration (FDA) and Subsequently Withdrawn From the US Market

Supplemental Material, Risk-Benefit_Manuscript_revised_supporting_material_20171025a_w_tables2 for Analysis of the Risks and Benefits of New Chemical Entities Approved by the US Food and Drug Administration (FDA) and Subsequently Withdrawn From the US Market by Peter A. Patriarca, R. Michael Van Auken, and Scott A. Kebschull in Therapeutic Innovation & Regulatory Science